INC Research ("INC" or the Company) is a global contract research organization providing clinical development services for the biopharmaceutical and medical device industries.

According to the Complaint, on May 10, 2017, the Board caused the Company to enter into an agreement and plan of merger (“Merger Agreement”), pursuant to which each share of common stock of inVentiv will automatically be cancelled and will cease to exist, and will thereafter represent the right to receive a number of newly issued shares of INC common stock equal to the per share merger consideration to be paid in accordance with the Merger Agreement.

The Complaint alleges on June 30, 2017, in order to convince INC stockholders to vote in favor of the Proposed Merger, the Board authorized the filing of a materially incomplete and misleading Definitive Proxy Statement with the Securities and Exchange Commission, in violation of Sections 14(a) and 20(a) of the Exchange Act.

This case was voluntarily dismissed on November 1, 2017.